

## **PROGRAM**

### *XIII RAISA GORBACHEVA MEMORIAL MEETING*

#### **HEMATOPOIETIC STEM CELL TRANSPLANTATION. GENE AND CELLULAR THERAPY**

**September 19-21, 2019**

**St. Petersburg, Russia**

#### **ORGANIZERS**

- Pavlov First Saint Petersburg State Medical University , Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, St. Petersburg, Russia
- Foundation for Development of Bone Marrow Transplantation, St. Petersburg, Russia

#### **VENUE**

SOKOS Hotel Olympia Garden.  
Halls AMERICA and ATHENS  
Bataiskii pereulok, 3A  
190013, St. Petersburg, Russia  
+7-812-335-22-70

#### **WORKING LANGUAGES**

- Russian
- English

Simultaneous translation will be provided

**Honorary Chairman**

GORBACHEV Mikhail, Moscow, Russia  
HELMANN Rüdiger, Heidelberg University, ELN Foundation, Weinheim, Germany  
KRÖGER Nicolaus, Hamburg, Germany  
BAGNENKO Sergey, St.Petersburg, Russia  
RUMYANTSEV Alexander, Moscow, Russia

**Chairman**

AFANASYEV Boris, St.Petersburg, Russia

**International organizing committee**

ZANDER Axel, Hamburg, Germany  
WAGEMAKER Gerard, Rotterdam, the Netherlands  
FEHSE Boris, Hamburg, Germany  
POPOVA Marina, St.Petersburg, Russia  
MOISEEV Ivan, St.Petersburg, Russia

**Local Organizing committee**

KULAGIN Alexander, St.Petersburg, Russia  
VOLKOVA Alisa, St.Petersburg, Russia  
MARKOVA Inna, St.Petersburg, Russia  
VITRISHCHAK Alina, St.Petersburg, Russia  
MOROZOVA Elena, St.Petersburg, Russia  
MIKHAILOVA Natalia, St.Petersburg, Russia  
ZUBAROVSKAYA Lyudmila, St.Petersburg, Russia  
CHUKHLOVIN Alexey, St.Petersburg, Russia  
GOLOSHCHAPOV Oleg, St.Petersburg, Russia  
SHVETSOV Alexander, St.Petersburg, Russia  
LEPIK Elena, St.Petersburg, Russia  
LEPIK Kirill, St.Petersburg, Russia  
TSVETKOV Nikolay, St.Petersburg, Russia  
AFANASYEVA Xenia, St.Petersburg, Russia  
FEDOROVA Lyudmila, St.Petersburg, Russia  
BEINAROVICH Anastasiya, St.Petersburg, Russia

**Address**

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation,  
Pavlov First Saint Petersburg State Medical University  
Roentgen Str. 12, 197022, St.Petersburg, Russia  
Tel.: + 7 (812) 338 6265, + 7 (812) 338 6261  
Fax: + 7 (812) 338 6265, + 7 (812) 338 6609  
E-mail: [coordinatorbmt@gmail.com](mailto:coordinatorbmt@gmail.com), [bmt-meduniversity@spb-gmu.ru](mailto:bmt-meduniversity@spb-gmu.ru)  
Web-site: [www.fdbmtspb.com](http://www.fdbmtspb.com) [www.spb-gmu.ru](http://www.spb-gmu.ru)



Dear friends!

Dear colleagues!

Dear Ladies and Gentlemen!

It is a great honor to welcome you again at the XIII Raisa Gorbacheva memorial Meeting in Saint Petersburg.

We express my sincere gratitude for your intention to take part in the work of the Symposium.

The Russian government has allocated a large funding for the development of various national projects. One of the priority areas is the national project on healthcare improvement. In the budget allocation, special attention is devoted to oncology.

There is no doubt that the planned funds will cover the purchase and modernization of medical equipment, extended use of novel medicines, construction of new medical centers. However, one should acknowledge that material and technical modernization of the healthcare system will not lead to the expected success without competent specialists.

The educational scope is one of the most significant priorities of our Symposium.

There is a good tradition to invite world recognized experts with lectures.

We want to welcome all our guests from Russia, Belarus, Kazakhstan, Germany, USA, the Netherlands, Finland, Norway, Israel, France, Poland, Brazil, Spain, Portugal. Your knowledge always attracts our hematologists, oncologists from Russia and other countries.

Our annual meetings reveal great opportunities for sharing experience and new achievements to the professional community of oncologists – hematologists.

Currently, there is a trend towards immunotherapy in hematology. This trend is only the beginning of a whole spectrum of novel therapies in oncology and hematology.

In the next decade, very interesting changes will occur that will strengthen the importance of immunotherapy of cancer. Despite that HSCT will remain the crucial method for the treatment of hematological diseases. And for oncological diseases, allogeneic HSCT will create a good platform for the use of immunotherapy and the development of new drugs.

We wish you fruitful and interesting work at the symposium, establishing new professional contacts and start ups.

We wish you once again plunge into the enchanting atmosphere of St. Petersburg, have a great time and enjoy the beauty of the city on the banks of the Neva, which over time becomes more and more attractive.

Rector of Pavlov First Saint Petersburg State  
Medical University  
Sergey F. Bagnenko

Director of Raisa Gorbacheva Memorial  
Institute  
for Pediatric Oncology Hematology  
Transplantation  
Boris V. Afanasyev

September 19, Thursday

08.00-16.00	<b>Registration of participants</b>
-------------	-------------------------------------

**PRE CONGRESS DAY**  
**Hall AMERICA**

<p>Scientific medical dispute with the support of <b>BMS Company</b>  <b>90 minutes on immunotherapy for Hodgkin's lymphoma</b>  <b>Chairmen:</b>          AFANASYEV Boris (St. Petersburg, Russia)          PTUSHKIN Vadim (Moscow, Russia)</p>		
09.00-09.05	<p>Introduction          AFANASYEV Boris (St. Petersburg, Russia)          PTUSHKIN Vadim (Moscow, Russia)</p>	
<p>Immunooncology in oncohematology in Russia: 2 years together</p>		
09.05-09.20	MIKHAILOVA Natalia (St. Petersburg, Russia)	Place control point inhibitors in the treatment of Hodgkin's lymphoma (except for hematopoietic stem cells transplant issues)
<p><b>Panel discussion</b></p> <p><b>Panel experts</b>          MIKHAILOVA Natalia (St. Petersburg, Russia)          LEPIK Kirill (Moscow, Russia)          DYOMINA Elena (Moscow, Russia)          SARZHEVSKIY Vladislav (Moscow, Russia)          POSPELOVA Tatyana (Moscow, Russia)          KAPLANOV Kamil (Volgograd, Russia)</p>		
09.20-09.35	AFANASYEV Boris (St. Petersburg, Russia)	Immunotherapy and autologous and allogeneic hematopoietic stem cells transplant: BEFORE, AFTER or INSTEAD? Q&A
09.35-09.45	FEDOROVA Lyudmila (St. Petersburg, Russia)	STOP therapy: can it be stopped? Is re-appointment of nivolumab effective? (re-treatment) Q&A
09.45-09.55	PTUSHKIN Vadim (Moscow, Russia)	The phenomenon of the restoration of sensitivity to chemotherapy after control points inhibitors Q&A
09.55-10.05	LEPIK Kirill (Moscow, Russia)	Actual safety issues in nivolumab usage Q&A
10.05-10.15	DYOMINA Elena (Moscow, Russia)	Features of assessment of therapy response: how to recognize pseudoprogression Q&A
10.15-10.25	POPOVA Marina (St. Petersburg, Russia)	The use of immunotherapy in HIV-infected patients Q&A
10.25-10.30	<p>Closing remarks          AFANASYEV Boris (St. Petersburg, Russia)</p>	
<p><b>AbbVie Company</b></p>		
10.30-11.00	<p><b>Panel discussion</b>  <b>Acute leukemia in Russia: past, present, future</b></p> <p>MASCHAN Mikhail (Moscow, Russia)          PAROVICHNIKOVA Elena (Moscow, Russia)          AFANASYEV Boris (St. Petersburg, Russia)          BONDARENKO Sergey (St. Petersburg, Russia)          PTUSHKIN Vadim (Moscow, Russia)</p>	

11.00-11.30	PTUSHKIN Vadim (Moscow, Russia)	Acute myeloid leukemia: the efficacy and safety of the Venetoclax in international studies
11.30-12.00	PAROVICHNIKOVA Elena (Moscow, Russia)	Experience of Venetoclax usage: from clinical studies to routine practice
12.00-12.15 Coffee-break		
<b>ASTRAZENICA Company</b>		
12.15-12.45	VOROBYEV Vladimir (Russia)	Outstanding issues and needs in relapsed and refractory mantle-cell lymphoma
<b>NOVARTIS Company</b>		
<b>New treatment options for aplastic anemia: eltrombopag in the 1st line of therapy</b>		
12.45-13.25	MIKHAILOVA Elena (Moscow, Russia)	Classical and modern approaches in IST for aplastic anemia patients
13.25-13.40	GORONKOVA Olga (Moscow, Russia)	Eltrombopag in treatment of children and young adults with acquired aplastic anemia
13.40-14.15	KULAGIN Alexander (St. Petersburg, Russia)	New options of 1st line therapy for aplastic anemia
<b>Johnson&amp;Johnson LLC Company</b>		
14.15-14.30	IVANOVA Maria (St. Petersburg, Russia)	Place of ibrutinib in therapy of chronic myeloid leukemia patients with hematopoietic stem cells transplant indication
14.30-14.45	DARSKAYA Elena (St. Petersburg, Russia)	Current view and perspectives of treatment with monoclonal antibodies for multiple myeloma
<b>CSL Behring</b>		
14.45-15.00	BABICHEVA Laly (Moscow, Russia)	Secondary Immunodeficiency in oncohematology
15.00 – 16.00 Lunch		
<b>SANOFI Company</b>		
16.00-16.30	GARDERET Laurant (Paris, France)	Management of relapsed and refractory multiple myeloma with novel monoclonal antibody-based regimens
<b>TAKEDA Company</b>		
<b>Takeda hematology – new reality</b>		
16.30-16.50	AFANASYEV Boris (St. Petersburg, Russia)	Introduction. Classical HL: will the treatment paradigm change?
16.50-17.10	MIKHAILOVA Natalia (St. Petersburg, Russia)	HL relapses: how are the treatment results to be improved?
17.10-17.30	PTUSHKIN Vadim (Moscow, Russia)	Experience of Moscow Hematology Center in the treatment of Hodgkin Lymphoma
17.30-17.50	GARDERET Laurant (Paris, France)	Ixazomib site in the treatment of patients with relapsed / refractory multiple myeloma
17.50-18.00 Coffee-break		
<b>PFIZER Company</b>		
18.00-18.20	GOLOSHCHAPOV Oleg (St. Petersburg, Russia)	New trends in the controls of infectious complications
18.20-18.40	PAINA Olesya (St. Petersburg, Russia)	Antifungal treatment in children with acute leukemia after chemotherapy and allogeneic hematopoietic stem cells transplant
18.40-19.00	MOROZOVA Elena (St. Petersburg, Russia)	Allogeneic hematopoietic stem cells transplant in advanced phases of chronic myeloid leukemia

**September 19th, Thursday**  
**Hall ATHENS**  
**Cell & Gene Therapy Day**

<b>09:00-11:30 State-of-the-Art Gene Therapy</b>		
<b>Chairman:</b>		
WAGEMAKER Gerard (Rotterdam, The Netherlands)		
IVICS Zoltan (Langen, Germany)		
09.00-09.05	AFANASYEV Boris (St-Petersburg, Russia)	Opening the Cell & Gene Therapy Day
09.05-09.25	WAGEMAKER Gerard (Rotterdam, The Netherlands)	State-of-the-Art Gene Therapy
09.30-09.50	IVICS Zoltan (Langen, Germany)	Non-viral therapeutic genome engineering
09.55-10.10	EHRKE-SCHULZ Eric (Witten, Germany)	AdV and AAV as efficient systems for the delivery of genome editing tools
10.15-10.25	SHAKIROVA Alyona (St-Petersburg, Russia)	Optimization of TALEN mediated gene editing efficiency in hematopoietic stem cells
10.30-10.40	TIMIN Alexander (St-Petersburg, Russia)	Bioengineering strategies to accelerate stem cell therapeutics
10.45-10.55	MUSLIMOV Albert (St-Petersburg, Russia)	Polymeric micro- and nano-carriers as a universal platform for delivery of biomolecules to therapeutic relevant cells
10.55-11.00	Q&A	
<b>11.00 – 11.15 Coffee break</b>		
<b>11:15-12:15 Regulatory and Development aspects Cell &amp; Gene Therapy</b>		
<b>Chairman:</b>		
SAMSONOV Mikhail (Moscow, Russia)		
FEHSE Boris (Hamburg, Germany)		
11.15-11.20	SAMSONOV Mikhail (Moscow, Russia)	Current state and updates of the legal framework for the development of Cell & Gene Therapies
11.20-11.40	MERKULOV Vadim, MELNIKOVA Ekaterina (Moscow, Russia)	Legal aspects of registration of Cell & Gene Therapies in the Russian Federation
11.40-11.45	MASCHAN Michael (Moscow, Russia)	Challenges of regulatory in application of Cell & Gene Therapies: first Russian academia experience
11.45-11.50	KULEMZIN Sergey (Novosibirsk, Russia)	Challenges of regulatory in development of Cell & Gene Therapies: first Russian academia experience
11.50-11.55	IVICS Zoltan (Langen, Germany)	European experts' opinion on challenges of regulatory and development Cell & Gene Therapies
11.55-12.00	ZAIAC Michael (Basel, Switzerland)	Pioneer Industry experience in development and registration of Cell & Gene Therapies
12.00-12.15	Q&A	
<b>12.15 – 12.30 Coffee break</b>		
<b>12:30-14:20 State-of-the-Art Cell Therapy (part 1)</b>		
<b>Chairman:</b>		
KOLB Hans-Jochem (München, Germany)		
AFANASYEV Boris (St-Petersburg, Russia)		
12.30-12.50	KOLB Hans-Jochem (München, Germany)	State-of-the-Art Cell Therapy
12.55-13.15	AFANASYEV Boris (St-Petersburg, Russia)	Cancer Immunotherapy

13.20-13.40	DROPULIC Boro (Gaithersburg, ML, USA)	CAR-T: hematology & beyond
13.45-14.00	KULEMZIN Sergey (Novosibirsk, Russia)	Genome engineering of “next-gen” human NK cell lines for anticancer therapy: challenges and perspectives
14.05-14.15	BELOVEZHETS Tatiana (Novosibirsk, Russia)	Ofatumumab-based CD20-specific CAR: in vitro and in vivo activity
14.15-14.20	Q&A	
<b>14.20 – 15.20 Lunch</b>		
<b>15:20-16:45 State-of-the-Art Cell Therapy (part 2)</b>		
<b>Chairman:</b> DROPULIC Boro (Gaithersburg, ML, USA) MASCHAN Michael (Moscow, Russia)		
15.20-15.40	FEHSE Boris (Hamburg, Germany)	CAR-T cell therapy – single-centre experience from Hamburg
15.45-16.05	MASCHAN Michael (Moscow, Russia)	CD19 CAR-T in pediatric B-lineage ALL: first experience in the academic medical center setting
16.10-16.20	ZAIAC Michael (Basel, Switzerland)	CD19 directed CART therapy with a focus on tisagenlecleucel
16.25-16.35	PETUKHOV Aleksey (St-Petersburg, Russia)	Allogenic CAR-T – Almazov Center Experience
16.40-16.50	CHIKAEV Anton (Novosibirsk, Russia)	CD19 CAR. Siberian version
16.50-16.55	Q&A	
<b>16.55 – 17.00 Coffee break</b>		
<b>17:00-19:00 Round table: Cell &amp; Gene Therapy for HIV cure</b>		
<b>Chairman:</b> AFANASYEV Boris (St-Petersburg, Russia) GUSEV Denis (St-Petersburg, Russia)		
17.00-17.05	AFANASYEV Boris (St-Petersburg, Russia)	Introduction & Opening the Discussion
17.05-17.10	GUSEV Denis (St-Petersburg, Russia)	Current state of HIV epidemiology in St-Petersburg
17.10-17.20	ROGACHEVA Yulia (St-Petersburg, Russia)	Case presentation (auto-HSCT) Moderator MIKHAILOVA Natalia (St-Petersburg, Russia)
17.20-17.30	POPOVA Marina (St-Petersburg, Russia)	Case presentation (allo-HSCT) Moderator SCHULZE ZUR WIESCH Julian (Hamburg, Germany)
17.30-17.50	SCHULZE ZUR WIESCH Julian (Hamburg, Germany)	"Understanding HIV cure: T cell immunology in the transplant setting- the Icistem consortium"
17.55-18.10	TARANIN Alexander (Novosibirsk, Russia)	Non-viral antigens priming bnAb lineages as components of an anti-HIV vaccine
18.15-18.25	FEHSE Boris (Hamburg, Germany)	Genome editing for HIV cure
18.30-18.40	DROPULIC Boro (Gaithersburg, ML, USA)	Anti-HIV CAR-T
18.45-18.55	ZAKURDAEVA Kristina (Moscow, Russia)	“Game of Genomes”: to be continued
18.55-19.00	Discussion & Closing remarks	

## HALL MOSCOW

<b>Psychological, Medical, Physical and Social Rehabilitation in hematopoietic stem cells transplant clinic</b>		
<b>Moderators:</b>		
VOLKOVA Alisa (St.Petersburg, Russia)		
NIKITINA Tatyana (St.Petersburg, Russia)		
09.00-09.20	KHAIN Alina (Moscow, Russia)	Key recommendations on the psychological support of paediatric allogeneic hematopoietic stem cells transplant: the experience of Dmitry Rogachev Center
09.20-09.40	CHICHELNITSKAYA Serafima (Moscow, Russia)	"Sensory conflict" as a possible cause of impaired postural stability of children treated for cancer
09.40-10.00	MITRAKOV Nikolay (Moscow, Russia)	Perspectives of use of clinical video analysis of movements of pediatric patients receiving hematopoietic stem cells transplant
10.00-10.20	LEYDERMAN Ilya N. (Yekaterinburg, Russia)	Key principles of lipid emulsions administration in parenteral nutrition - efficiency and safety issues
10.20-10.40	VASHURA Andrey (Moscow, Russia)	Low-bacterial diet in children undergoing allogeneic hematopoietic stem cells transplant: the essence, key principles and unresolved issues
10.40-11.00	VOLKOVA Alisa (St.Petersburg, Russia) IONOVA Tatiana (St.Petersburg, Russia)	Family-oriented rehabilitation of children after hematopoietic stem cells transplant
11.00-11.20	KULIKOV Evgeniy (St.Petersburg, Russia)	Patient-controlled analgesia in hematopoietic stem cells transplant recipients with oral and gastrointestinal mucositis
11.20-11.40	TERENTIEV Fedor (St.Petersburg, Russia) POTAPCHUK Alla (St.Petersburg, Russia)	The impact of physical activity on the psychological and physical state of adolescent after hematopoietic stem cells transplant in an oncologic hospital
<b>11.20 – 12.00 Coffee-break</b>		
<b>Nurse session</b>		
<b>Moderators:</b>		
GOLOSHCHAPOV Oleg (Saint-Petersburg, Russia)		
SHVETSOV Alexander (Saint-Petersburg, Russia)		
12.00-12.15	PLESHCHENKOVA Olga (St.Petersburg, Russia)	Epidemiological screening for antibiotic-resistant infections
12.15-12.30	KHALETSKAYA Natalya (Minsk, Belarus)	Some aspects of nursing care for children after allogeneic hematopoietic stem cells transplant
12.30-12.45	KLIPININA Natalia (Moscow, Russia)	Psychological severities and professional adaptation of nurses at pediatric oncology/hematology/immunology
12.45-13.00	SHEPELEVA Lyubov (St.Petersburg, Russia)	Methodology of intraventricular administration of anticancer drugs through the Ommaya reservoir
13.00-13.15	APOSTOLOVA Anna (St.Petersburg, Russia)	Tactics of patients' care in graft versus host disease
13.15-13.30	SALTYKOVA Natalia (St.Petersburg, Russia)	Administration of nasogastric tubes and gastrostomy in hematopoietic stem cells transplant patients
13.30-13.45	SELEDTSOVA Svetlana (Irkutsk, Russia)	Peripheral implanted venous access. Experience of the chemotherapy department for lymphoproliferative neoplasms in Irkutsk Oncology Hospital
13.45-14.00	GRIGORIEVA Svetlana (Ust-Kamenogorsk, Kazakhstan)	Comparison of the effectiveness of water and alcohol solutions of chlorhexidine in the prevention of catheter-associated infections (CRBSI) in oncohematological patients
14.00-14.15	LESHCHUK Natalia (Moscow, Russia)	Clinical case of GVHD in nursi practice
<b>14.30-15.30 Lunch</b>		
15.30-16.00 Master class		



Vascular access in the clinic of oncology hematology and Bone marrow transplantation

**Moderators**

SALTYKOVA Natalia (St.Petersburg, Russia)

SINENKO Rimma (St.Petersburg, Russia)

SUVOROVA Arina (St.Petersburg, Russia)

**September 20, Friday**

**Symposium "Hematopoietic Stem Cell Transplantation. Gene and Cellular Therapy"**

**FIRST DAY**

08.00 – 16.00.	Registration of participants Hall, second floor
-------------------	--

**Hall AMERICA**

08.30-08.50		
<b>Opening ceremony</b>		
<b>Welcome speeches</b>		
BAGNENKO Sergey, Saint Petersburg, Russia		
KRÖGER Nicolaus, Hamburg, Germany		
NOVICHKOVA Galina, Moscow, Russia		
AFANASYEV Boris, Saint Petersburg, Russia		
<b>Special lectures</b>		
<b>Chairmen:</b>		
KRÖGER Nicolaus, Hamburg, Germany		
MASCHAN Mikhail, Moscow, Russia		
FENAUX Pierre, Paris, France		
08.50-09.00	Introduction to Robert P. Gale <i>By Boris AFANASYEV</i>	
09.00-09.25	<b><u>Raisa Gorbacheva memorial lecture</u></b> GALE Robert, Los Angeles, USA <b><i>Can immune therapy cure Acute myeloid leukemia</i></b>	
09.25-09.50	<b><u>Alexander Friedentstein memorial lecture</u></b> Dr. h. c. ZANDER Axel, Hamburg, Germany <b><i>Mesenchymal stem cell: stem cell: from bench to bedside</i></b>	
09.50-10.15	KRÖGER Nicolaus, Hamburg, Germany <b><i>Haploidentical stem cell transplantation</i></b>	
10.15-10.25	Q&A	
<b>10.25-10.35 Pause</b>		
10.35-11.00	Dr. h. c. WAGEMAKER Gerard, Rotterdam, the Netherlands <b><i>Current clinical implementation of gene therapy in rare, inherited disorders</i></b>	
11.00-11.25	KOLB Hans-Jochem, München, Germany <b><i>Late malignant and non-malignant effects in transplant patients</i></b>	
11.25-11.50	MASCHAN Mikhail, Moscow, Russia <b><i>Evolution of approach to hematopoietic stem cells transplant in pediatric leukemia: from haploidentical donors to CAR-T therapy</i></b>	
<b>Short presentation</b>		
11.50- 12.00	BONDARENKO Sergey (Saint Petersburg, Russia)	Choice of optimal time for allogeneic hematopoietic stem cells transplant in Acute myeloid leukemia : CR 1 or CR 2
12.00- 12.10	ALYANSKIY Alexander (Saint Petersburg, Russia)	Selection of optimal donor for allogeneic hematopoietic stem cells transplant
12.10- 12.20	Q&A	

<b>12.20-12.50 Coffee break</b>		
<b>Session 1. Different aspects of hematopoietic stem cells transplant</b>		
<b>Chairmen:</b>		
HEHLMANN Rüdiger (Heidelberg University, ELN Foundation, Weinheim, Germany)		
RUUTU Tapani (Helsinki, Finland)		
BASAK Grzegorz (Warsaw, Poland)		
12.50-13.05	HEHLMANN Rüdiger (Heidelberg University, ELN Foundation, Weinheim, Germany)	Better outcome by earlier diagnosis: High-risk ACA indicate progression to chronic myeloid leukemia blast crisis already at low blast levels
13.05-13.20	FENAUX Pierre (Paris, France)	Allogeneic hematopoietic stem cells transplant in myelodysplastic syndrome and chronic myelomonocytic leukemia: for which patients? As first line treatment or preceded by cytoreductive therapy?
13.20-13.35	BASAK Grzegorz (Warsaw, Poland)	Transplantation in elderly – sky is the limit
<b>Short presentations</b>		
13.35 – 13.45	MOROZOVA Elena (Saint Petersburg, Russia)	The results of allogeneic HSCT in patients with CML: single center experience
13.45-13.55	DROKOV Mikhail, POPOVA N. (Moscow, Russia)	Reconstitution of immune system after different regimen of graft-versus-host-disease prophylaxis
13.55-14.05	BEYNAROVICH Anastasiya (Saint Petersburg, Russia)	10-years experience of haploidentical transplantation: single center data
14.05-14.15	MOTORIN Dmitry (Saint Petersburg, Russia)	Hematopoietic stem cells transplant in chronic myeloid leukemia patients with blast crisis
14.15-14.25	MOISEEV Ivan (Saint Petersburg, Russia)	Evolution of graft-versus-host-disease prophylaxis and treatment regimens: leaving the Seattle nest
14.25-14.35	DOVYDENKO Maria (Moscow, Russia)	Haploidentical stem cells transplant with TCR alfa-beta /CD19 depletion in patients with hematological malignancies
14.35-14.45	Q&A	
<b>14.45 – 15.45 Lunch. Poster session</b>		
<b>Session 2 Different aspects of hematopoietic stem cells transplant</b>		
<b>Chairpersons:</b>		
ABECASIS Manuel (Lisboa, Portugal)		
GARDERET Laurant (Paris, France)		
ENGERT Andreas (Koeln, Germany)		
15.45-16.00	RUUTU Tapani (Helsinki, Finland)	Is there any role for corticosteroids in graft-versus-host-disease prophylaxis?
16.00-16.15	PINTO SIMOES Belinda (San Paolo, Brazil)	Multiple sclerosis: experience in adults
16.15-16.30	GARDERET Laurant (Paris, France)	Will autologous stem cell transplantation remain a treatment for multiple myeloma?
16.30-16.45	NIEDERWIESER Dietger (Leipzig, Germany)	The role of stem cell transplantation in the treatment of acute myeloid leukemia
<b>Short presentation</b>		
16.45-16.55	KIRGIZOV Kirill (Moscow, Russia)	Hematopoietic stem cell transplantation for children with multiple sclerosis in Russia
16.55-17.10	Q&A	

**Hall MOSCOW**

**15.00-15.30 Meet-the-expert session**

ZAIAC Michael (Basel, Switzerland)

**End of first day**

**September 21, Saturday**

**Symposium "Hematopoietic Stem Cell Transplantation. Gene and Cellular Therapy"**

**SECOND DAY**

**HALL AMERICA**

<b>Session 3 Hematopoietic stem cells transplant: focus on Lymphomas</b>		
<b>Chairpersons:</b>		
SCHMITZ Norbert (Hamburg, Germany)		
SUREDA Anna (Madrid, Spain)		
SARZHEVSKIY Vladislav (Moscow, Russia)		
09.00 – 09.15	SUREDA Anna (Madrid, Spain)	To allograft or not allograft patients with Hodgkin's lymphoma in the era of targeted therapy
09.15-09.30	ABECASIS Manuel (Lisboa, Portugal)	Hematopoietic stem cell transplantation as a consolidation strategy in peripheral T-cell lymphomas
09.30-09.45	SCHMITZ Norbert (Muenster, Germany)	The role of autologous and allogeneic hematopoietic stem cells transplant in the treatment of T-cell Lymphoma
09.45-10.00	AFANASYEV Boris (Saint Petersburg, Russia)	Allogeneic hematopoietic stem cells transplant in relapsed/refractory Hodgkin lymphoma: focus on immunotherapy
10.00-10.15	ENGERT Andreas (Köln, Germany)	Overview on Hodgkin Lymphoma including the latest aspects on checkpoint inhibition
10.15-10.30	SARZHEVSKIY Vladislav (Moscow, Russia)	The role and place of autologous hematopoietic stem cell transplantation in the treatment of Hodgkin's lymphoma
<b>Short presentations</b>		
10.30-10.40	FEDOROVA Lyudmila (Saint Petersburg, Russia)	Nivolumab retreatment in patients with relapsed/refractory classical Hodgkin lymphoma
10.40-10.50	LEPIK Kirill (Saint Petersburg, Russia)	Nivolumab treatment regimen optimization in patients with refractory and relapsed classical Hodgkin lymphoma
10.50-11.00	Q&A	
<b>11.00 - 11.15 Coffee break</b>		
<b>Session 4 Pediatric session</b>		
<b>Chairpersons:</b>		
ALEYNIKOVA Olga (Minsk, Belarus)		
ZUBAROVSKAYA Lyudmila (St. Petersburg, Russia)		
BIELACK Stefan (Stuttgart, Germany)		
11.15-11.30	KOHLSCHÜTTER Alfried (Hamburg, Germany)	Effective intrathecal enzyme replacement therapy for children with CLN2 disease, a genetic disorder causing dementia and early death
11.30-11.45	ALEYNIKOVA Olga (Minsk, Belarus)	The results of hematopoietic stem cells transplant for pediatric leukemias in Republic of Belarus
11.45-12.00	BIELACK Stefan (Stuttgart, Germany)	What is the evidence for autologous hematopoietic stem cells transplant in children with pediatric malignancies?
<b>Short presentation</b>		
12.00-12.10	MARKOVA Inna (Saint Petersburg, Russia)	Allogeneic hematopoietic stem cells transplant in children and adults with relapsed/refractory B-ALL: focus on anti-CD19, anti-CD22 monoclonal antibodies
12.10-	BYKOVA Tatiana (Saint Petersburg, Russia)	Graft failure and poor graft function in children undergoing allogeneic

12.20	Petersburg, Russia)	hematopoietic stem cells transplant
12.20-12.30	KOZLOV Andrey (Saint Petersburg, Russia)	Hematopoietic stem cell transplantation in children and adolescents with lymphomas: a single-centre, 25-year experience
12.30-12.40	Q&A	
<b>12.40 – 13.45 Lunch. Poster session</b>		
<b>Session 5 Hematopoietic stem cells transplant: focus on Bone Marrow Failure</b>		
<b>Chairpersons:</b>		
NOVICHKOVA Galina (Moscow, Russia)		
MITTELMAN Moshe (Tel-Aviv, Israel)		
NIEDERWIESER Dietger (Leipzig, Germany)		
13.45-14.00	NOVICHKOVA Galina,	Immunosuppressive therapy vs immunosuppressive therapy + eltrombopag in children and adolescents with acquired aplastic anemia: Early results of a randomized multicenter study
14.00-14.15	MITTELMAN Moshe (Tel-Aviv, Israel)	Treatment of Myelodysplastic Syndromes: Today and Tomorrow
14.15-14.30	KULAGIN Alexander (Saint Petersburg, Russia)	Current management of aplastic anemia: Focus on older patients
<b>Short presentations</b>		
14.30-14.40	RUDAKOVA Tatiana (Saint Petersburg, Russia)	Risk factors, outcomes, and therapeutic options for severe poor graft function after allogeneic hematopoietic stem cell transplant in adult patients
14.40-14.50	VASILIEVA Vera (Moscow, Russia)	Clinical efficacy and immune effects of extracorporeal photopheresis in patients with chronic graft-versus-host-disease
14.50-15.00	Q&A	
<b>15.00 – 15.15 Coffee break</b>		
<b>Session 6 Different aspects of hematopoietic stem cells transplant: basic research</b>		
KOLB Hans-Jochem (München, Germany)		
BORSET Magne (Trondheim, Norway)		
Dr. h. c. ZANDER Axel (Hamburg, Germany)		
15.15-15.30	BEIDER Katia (Tel Hashomer, Israel)	The role of microenvironment for hematological malignancies: potential therapeutic implications
15.30-15.45	KOLB Hans-Jochem (München, Germany)	Immunotolerance by chimerism
15.45-16.00	BORSET Magne (Trondheim, Norway)	Immune checkpoint inhibition in the treatment of multiple myeloma
16.00-16.15	Dr. h. c. FEHSE Boris (Hamburg, Germany)	Usage of digital PCR for posttransplant diagnostics
<b>Short presentations</b>		
16.15-16.25	KUZMINA Larisa (Moscow, Russia)	Mesenchymal stem cell: in treatment of steroid refractory acute graft-versus-host-disease
16.25-16.35	BARKHATOV Ildar (St-Petersburg, Russia)	Characteristics of recipient's bone marrow stromal cells in the context of posttransplant hematopoiesis reconstitution
16.35-16.45	EFIMOV Grigory (Moscow, Russia)	Minor Histocompatibility Antigen-Specific CD8+ T Cells for Immunotherapy of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
<b>16.45-17.00 Pausa</b>		
17.00-17.30	<b>SPECIAL LECTURE</b> HOELZER Dieter, Frankfurt, Germany <i>How do we proceed to Frontline Immunotherapy in acute lymphoblastic leukemia and what will be the</i>	

	<i>place of hematopoietic stem cells transplant?</i>	
<b>Poster session awards</b>		
<b>Chairpersons:</b>		
RUUTU Tapani, Helsinki, Finland		
MIKHAILOVA Natalia, St. Petersburg, Russia		
KULAGIN Alexander, St. Petersburg, Russia		
<b>BEST POSTERS</b>		
17.30-17.40	III prize	
17.40-17.50	II prize	
17.50-18.00	I prize	
18.00	AFANASYEV Boris (St. Petersburg, Russia)	Closing remarks